Clinical trials: Newly Diagnosed Multiple Myeloma
Multiple Myeloma
An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients
According to international guidelines, upfront therapy for transplant eligible myeloma patients should include triplet induction containing proteasome inhibitor and immunomodulatory agent, autologous stem cell transplant, PI+Imid…
- Trial name
- IFM 2018-04 (NCT03606577)
- Testing
- Carfilzomib, Daratumumab, Lenalidomide
- Where
- 12 sites in France
- Volunteers
- 50 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma
Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
This is a phase 1/2, open label, study designed to assess the safety and clinical activity of different Belantamab Mafodotin doses in combination with lenalidomide and dexamethasone.
- Trial name
- BelaRd (NCT04808037)
- Testing
- Belantamab mafodotin
- Where
- Greece
- Volunteers
- 66 people
- Sponsor
- Hellenic Society of Hematology
Multiple Myeloma
Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma
1. Study Title A Single-Center, Open-Label, Single-Arm Clinical Study of Sequential Anti-BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-Eligible Newly Diagnosed Multiple Myeloma…
- Trial name
- AUTO-CAR-T (NCT06913192)
- Testing
- CAR-T
- Volunteers
- 50 people
- Sponsor
- Xuzhou Medical University
Multiple Myeloma, Newly Diagnosed Multiple Myeloma
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
- Trial name
- DREAMM-10 (NCT06679101)
- Testing
- Belantamab mafodotin, Lenalidomide, Dexamethasone
- Where
- 181 sites in United States, Argentina and 22 more
- Volunteers
- 520 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma, Myeloma
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Newly diagnosed Multiple Myeloma patients who are ineligible for a transplant have inferior outcomes to that of the transplant population.
- Trial name
- NCT03695744
- Testing
- Daratumumab, Bortezomib, Dexamethasone
- Where
- 2 sites in Singapore
- Volunteers
- 27 people
- Sponsor
- Singapore General Hospital
Multiple Myeloma
A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
This was a multicenter, open-label, randomized phase II study which were to enroll 112 newly diagnosed symptomatic multiple myeloma patients in a 1:1 fashion.
- Trial name
- PANORAMA4 (NCT02720510)
- Testing
- Revlimid, Velcade, dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Plasma Cell Myeloma
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well they work compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma.
- Trial name
- NCT01863550
- Testing
- Bortezomib, Carfilzomib, Dexamethasone
- Where
- 920 sites in United States, Puerto Rico
- Volunteers
- 1,087 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Multiple Myloma, Newly Diagnosed Multiple Myeloma (NDMM)
Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
This is a single-arm, dose-escalation exploratory study evaluating the safety and efficacy of RN1201, a BCMA/CD19-targeted allogeneic CAR-T cell therapy, in patients with newly diagnosed multiple myeloma.
- Trial name
- NCT07652138
- Testing
- BCMA/CD19-targeted allogeneic CAR-T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma, Myeloma Multiple
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
Isatuximab was developed on a sub-cutaneous (SC) administration format. SC administration is expected to be more convenient for the patient, with a much shorter duration of administration compared to the currently approved IV…
- Conditions
- Multiple Myeloma, Myeloma Multiple, Myeloma
- Trial name
- NCT05889221
- Testing
- Drug and medical device
- Where
- France
- Volunteers
- 74 people
- Sponsor
- Poitiers University Hospital
Multiple Myeloma
A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
The purpose of the study is to compare the efficacy and safety of daratumumab, lenalidomide and dexamethasone (DRd) to that of modified bortezomib, lenalidomide and dexamethasone (VRd-lite), in terms of progression-free survival…
- Trial name
- NCT06497738
- Where
- 6 sites in China
- Volunteers
- 112 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Multiple Myeloma
STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
This study will evaluate the safety and the efficacy of the MLN-DEXAMETHASONE, MLN-DEXAMETHASONE-CYCLOPHOSPHAMIDE, or MLN- THALIDOMIDE-DEXAMETHASONE induction combinations, followed by MLN maintenance in newly diagnosed elderly…
- Trial name
- NCT02586038
- Testing
- MLN9708, Dexamethasone, Cyclophosphamide
- Where
- Italy
- Volunteers
- 175 people
- Sponsor
- Mario Boccadoro
Multiple Myeloma
Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM
The purpose of this study is to compare the safety and efficacy of Lenalidomide versus Placebo maintenance following melphalan, prednisone and velcade induction therapy in newly diagnosed multiple myeloma.
- Trial name
- ARUMM (NCT02112175)
- Testing
- Lenalidomide
- Where
- 73 sites in Belgium, France and 3 more
- Volunteers
- 46 people
- Sponsor
- Celgene
Multiple Myeloma
Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone
Recent prospective multicenter phase II study assessed the efficacy and tolerability of lower dose lenalidomide (15mg) and dexamethasone (20mg) in frail patients with relapsed or refractory MM.
- Trial name
- LENDER (NCT03809780)
- Testing
- Lenalidomide, Dexamethasone
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Kosin University Gospel Hospital
Multiple Myeloma
Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM
1. Primary Objective To assess the response rate of sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Velcade, Thalidomide, Dexamethasone) induction therapy as a first line treatment for the patients with multiple…
- Trial name
- NCT00378755
- Testing
- velcade
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- Korean Multiple Myeloma Working Party
Multiple Myeloma
Isa-VRD in TIE HRMM
This is a multicenter, prospective, randomized controlled trial designed to compare the quadruplet regimen of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRD) with the standard triplet regimen (VRD) in newly…
- Trial name
- NCT07334535
- Testing
- Isatuximab, bortezomib, lenalidomide, dexamethason, Bortezomib, Lenalidomide, Dexamethasone
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Peking Union Medical College Hospital
Multiple Myeloma
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
The purpose of this original study is to determine the recommended phase 2 dose (RP2D) of TAK-079 when administered to participants with NDMM in combination with the backbone treatment regimen.
- Trial name
- NCT03984097
- Testing
- TAK-079, Lenalidomide, Dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Takeda
Multiple Myeloma, Comprehensive Geriatric Assessment
cGA in Newly-diagnosed Elderly MM Patients: a Multi-center, Prospective, Non-interventional Study.
This is a multi-center, prospective, non-interventional study. Eligible newly diagnosed elderly multiple myeloma (MM) patients will receive comprehensive geriatric assessment (cGA) including ECOG scale, questionaires of…
- Trial name
- NCT03122327
- Testing
- Questionaires
- Volunteers
- 200 people
- Sponsor
- Peking Union Medical College Hospital
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Multiple Myeloma
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
This study has 2 parts: a Dose Escalation Part and a Dose Expansion Part. The goal of the Dose Escalation Part of this clinical research study is to find the highest tolerable dose of nivolumab in combination with ipilimumab and…
- Trial name
- NCT03283046
- Testing
- Nivolumab, Lenalidomide, Dexamethasone
- Sponsor
- M.D. Anderson Cancer Center
Newly Diagnosed Multiple Myeloma (NDMM)
Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
To conduct a multicenter, prospective observational cohort study to investigate first-line immunotherapy patterns and clinical outcomes in NDMM patients in China.
- Trial name
- PRIMARY (NCT07296627)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Peking University People's Hospital
Myeloma, Multiple
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
A randomized Phase II clinical trial will be conducted to assess the impact on progression free survival (PFS) with the addition of ixazomib and daratumumab to lenalidomide as a maintenance treatment following induction with…
- Trial name
- NCT04009109
- Testing
- Lenalidomide, Ixazomib, Daratumumab Injection
- Where
- 7 sites in United States
- Volunteers
- 79 people
- Sponsor
- Alliance Foundation Trials, LLC.